Rhumbline Advisers Purchases 7,408 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Rhumbline Advisers boosted its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 4.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 180,964 shares of the company’s stock after purchasing an additional 7,408 shares during the period. Rhumbline Advisers owned about 0.12% of Xeris Biopharma worth $613,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of XERS. R Squared Ltd bought a new stake in shares of Xeris Biopharma during the 4th quarter worth $42,000. Wealth Enhancement Advisory Services LLC acquired a new position in Xeris Biopharma during the third quarter worth about $35,000. Quantbot Technologies LP bought a new position in shares of Xeris Biopharma in the third quarter worth about $44,000. Janney Montgomery Scott LLC boosted its stake in shares of Xeris Biopharma by 31.4% in the 4th quarter. Janney Montgomery Scott LLC now owns 23,000 shares of the company’s stock valued at $78,000 after purchasing an additional 5,500 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Xeris Biopharma by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 31,611 shares of the company’s stock valued at $107,000 after purchasing an additional 2,954 shares during the last quarter. Institutional investors and hedge funds own 42.75% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on XERS. HC Wainwright reissued a “buy” rating and issued a $8.00 price objective (up previously from $6.60) on shares of Xeris Biopharma in a research note on Friday. Piper Sandler reiterated a “neutral” rating and issued a $4.00 price target (up from $3.00) on shares of Xeris Biopharma in a research note on Friday. Finally, Jefferies Financial Group restated a “buy” rating and set a $6.00 price objective (up previously from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th.

Xeris Biopharma Stock Performance

XERS stock opened at $4.24 on Friday. The company has a market capitalization of $632.10 million, a P/E ratio of -9.42 and a beta of 2.32. The company has a fifty day moving average price of $3.55 and a 200-day moving average price of $3.24. Xeris Biopharma Holdings, Inc. has a 52-week low of $1.69 and a 52-week high of $4.50.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.